[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2006065938A3 - Cancer-specific spanx-n markers - Google Patents

Cancer-specific spanx-n markers Download PDF

Info

Publication number
WO2006065938A3
WO2006065938A3 PCT/US2005/045317 US2005045317W WO2006065938A3 WO 2006065938 A3 WO2006065938 A3 WO 2006065938A3 US 2005045317 W US2005045317 W US 2005045317W WO 2006065938 A3 WO2006065938 A3 WO 2006065938A3
Authority
WO
WIPO (PCT)
Prior art keywords
spanx
expression
cancer
subfamily
genes
Prior art date
Application number
PCT/US2005/045317
Other languages
French (fr)
Other versions
WO2006065938A2 (en
Inventor
Natalay Kouprina
Vladimir Larionov
Paul Goldsmith
J Carl Barrett
Original Assignee
Us Gov Health & Human Serv
Natalay Kouprina
Vladimir Larionov
Paul Goldsmith
J Carl Barrett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Natalay Kouprina, Vladimir Larionov, Paul Goldsmith, J Carl Barrett filed Critical Us Gov Health & Human Serv
Priority to EP05854102A priority Critical patent/EP1838872A2/en
Priority to AU2005316532A priority patent/AU2005316532A1/en
Priority to CA002591918A priority patent/CA2591918A1/en
Publication of WO2006065938A2 publication Critical patent/WO2006065938A2/en
Publication of WO2006065938A3 publication Critical patent/WO2006065938A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides SPANX polypeptides, nucleic acids and antibodies that are useful for detecting and treating cancer. The invention relates to a new subfamily of SPANX genes, SPANX-N1, SPANX-N2, SPANX-N3 SPANX-N4 and SPANX-N5. In contrast to the previously identified SPANX-A/D subfamily, expression of SPANX-N genes is not restricted to testis, and was detected in normal prostate, placenta, lung, colon, ovary and cervix tissues. Comparison of matched normal/tumor tissues revealed a predominant activation of only one member of the subfamily, SPANX-N1, in tumors, indicating that expression of this gene is diagnostic of cancer. Methods and reagents described herein permit detection and treatment of cancers associated with SPANX-N1 expression.
PCT/US2005/045317 2004-12-15 2005-12-15 Cancer-specific spanx-n markers WO2006065938A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05854102A EP1838872A2 (en) 2004-12-15 2005-12-15 Cancer-specific spanx-n markers
AU2005316532A AU2005316532A1 (en) 2004-12-15 2005-12-15 Cancer-specific SPANX-N markers
CA002591918A CA2591918A1 (en) 2004-12-15 2005-12-15 Cancer-specific spanx-n markers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63681104P 2004-12-15 2004-12-15
US60/636,811 2004-12-15

Publications (2)

Publication Number Publication Date
WO2006065938A2 WO2006065938A2 (en) 2006-06-22
WO2006065938A3 true WO2006065938A3 (en) 2007-02-08

Family

ID=36588517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045317 WO2006065938A2 (en) 2004-12-15 2005-12-15 Cancer-specific spanx-n markers

Country Status (4)

Country Link
EP (1) EP1838872A2 (en)
AU (1) AU2005316532A1 (en)
CA (1) CA2591918A1 (en)
WO (1) WO2006065938A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
CN114262683B (en) * 2022-03-01 2022-06-17 中国科学院动物研究所 Bacterial preparation for expressing VEGFR 3D 2 polypeptide and construction method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020607A2 (en) * 2002-08-30 2004-03-11 Texas Tech University SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2004048518A2 (en) * 2002-11-26 2004-06-10 Incyte Corporation Organelle-associated proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020607A2 (en) * 2002-08-30 2004-03-11 Texas Tech University SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
WO2004048518A2 (en) * 2002-11-26 2004-06-10 Incyte Corporation Organelle-associated proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt 7 December 2004 (2004-12-07), XP002394415, retrieved from EBI Database accession no. Q5VSR9 *
HOPP T P ET AL: "PREDICTION OF PROTEIN ANTIGENIC DETERMINANTS FROM AMINO ACID SEQUENCES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, NEW YORK, NY, US, vol. 78, no. 6, 1 June 1981 (1981-06-01), pages 3824 - 3828, XP000647365 *
KOUPRINA NATALAY ET AL: "Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27", GENOME RESEARCH, vol. 15, no. 11, November 2005 (2005-11-01), pages 1477 - 1486, XP002394412, ISSN: 1088-9051 *
KOUPRINA NATALAY ET AL: "The SPANX gene family of cancer/testis-specific antigens: Rapid evolution and amplification in African great apes and hominids.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 9, 2 March 2004 (2004-03-02), pages 3077 - 3082, ISSN: 0027-8424 *
WERNER THOMAS: "Target gene identification from expression array data by promoter analysis", BIOMOLECULAR ENGINEERING, vol. 17, no. 3, March 2001 (2001-03-01), pages 87 - 94, XP002394413, ISSN: 1389-0344 *
ZENDMAN A J W ET AL: "The human SPANX multigene family: genomic organization, alignment and expression in male germ cells and tumor cell lines", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 309, no. 2, 8 May 2003 (2003-05-08), pages 125 - 133, XP004426689, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
EP1838872A2 (en) 2007-10-03
AU2005316532A1 (en) 2006-06-22
CA2591918A1 (en) 2006-06-22
WO2006065938A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
Hasan et al. Advances in pancreatic cancer biomarkers
WO2006008128A3 (en) Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
WO2006012361A3 (en) Genetic markers for predicting disease and treatment outcome
WO2008107134A3 (en) A method for detection of liver cancer, risk of liver cancer, risk of recurrence of liver cancer, malignancy of liver cancer and progression of liver cancer with time by using the methylated cytosine in basp1 gene and/or srd5a2 gene
WO2008063769A3 (en) Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2009108917A3 (en) Markers for improved detection of breast cancer
WO2005118876A3 (en) Egfr mutations
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2001075177A3 (en) Tumor markers in ovarian cancer
WO2007123772A3 (en) Genes involved in estrogen metabolism
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
MX2007008984A (en) Cancer markers and detection methods.
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2009007958A3 (en) Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes
Hauch et al. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients
Stepan et al. Molecular margins in head and neck cancer: Current techniques and future directions
Schmidt et al. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
JP2002527758A (en) Methods for diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2006065938A3 (en) Cancer-specific spanx-n markers
ATE553112T1 (en) TTK IN DIAGNOSIS AND AS A THERAPEUTIC TARGET IN CANCER
Arencibia et al. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer
Zaitsu et al. Loss of heterozygosity of PTEN (encoding phosphate and tensin homolog) associated with elevated HER2 expression is an adverse prognostic indicator in gastric cancer
Stuopelytė et al. High-resolution melting-based quantitative analysis of RASSF1 methylation in breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2591918

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005316532

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005316532

Country of ref document: AU

Date of ref document: 20051215

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005316532

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005854102

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005854102

Country of ref document: EP